Trisenox Combination Regimen Induces High Rate of Responses

At the 10th International Myeloma Workshop, James Berenson, medical and scientific director of the Institute for Myeloma and Bone Cancer Research presented data from a multicenter, Phase II trial of a Trisenox combination regimen, known as MAC (melphalan, Trisenox and vitamin C), in relapsed or refractory multiple myeloma patients.

The data showed that 22 of the 37 patients evaluated achieved an objective response, with eight patients experiencing a decrease in serum M-protein of 50 percent or more and 14 patients experiencing a decrease in serum M-protein of between 25 to 49 percent. Of the 29 patients who had failed prior thalidomide or lenolinamide therapy, 14 patients responded to the Trisenox regimen.

In addition, seven out of 10 patients who had failed bortezomib therapy responded, and 10 out of 16 patients who had received prior melphalan therapy responded. The regimen was well-tolerated. The few significant adverse events included mild cytopenias, fluid retention and neuropathy. Trisenox (arsenic trioxide) is marketed in the U.S. and Europe by Cell Therapeutics.